Shares of Bionano Genomics (NASDAQ: BNGO) surged 9.52% in a 24-hour period following the release of its third-quarter 2025 financial results, which exceeded analyst expectations and showcased significant improvements in key metrics.

The genome mapping company reported Q3 revenue of $7.4 million, representing a 21% increase from $6.1 million in the same period last year and beating the analyst consensus estimate of $6.871 million. This growth was primarily driven by increased utilization among routine users and expanding adoption in key markets, including Japan. Bionano's gross margin saw a remarkable improvement, reaching 46% compared to a negative 139% in Q3 2024. The company also demonstrated strong cost management, reducing operating expenses by 66% to $11.9 million.

Looking ahead, Bionano provided an optimistic outlook for the fourth quarter and full year 2025. The company initiated Q4 2025 revenue guidance in the range of $7.5 to $7.9 million and reiterated its full-year 2025 revenue forecast of $26 to $30 million. Additionally, Bionano now expects to surpass 25 new optical genome mapping (OGM) system installations for the full year 2025, exceeding previous expectations. CEO Erik Holmlin commented, "We believe our performance in the third quarter and year-to-date validates our strategic shift and demonstrates our turn toward sustainable growth as our business stabilizes."